AL-LAD 150mcg Blotters

---

6-Allyl-6-nor-lysergic acid diethylamide, also known as N-allyl-nor-lysergic acid N,N-diethylamide, N-allyl-nor-LSD, or simply AL-LAD, is a novel psychedelic substance belonging to the lysergamide class. AL-LAD shares a chemical similarity with LSD and operates primarily by binding to serotonin receptors in the brain.

Historical Background

AL-LAD was first explored in 1984 by researchers Andrew J. Hoffman and David Nichols as part of a series of LSD analogs, which included compounds like ETH-LAD and PRO-LAD. Its effects in humans were later documented by Alexander Shulgin in his book "TiHKAL" ("Tryptamines I Have Known and Loved"), where it was described as "one of the several very potent compounds in a large series of nor-LSD analogues." In 2013, AL-LAD became available on the research chemical market, often marketed alongside other lysergamides such as 1P-LSD, ALD-52, and ETH-LAD as a legal, grey-market alternative to LSD.

User Experiences

User reports indicate that the effects of AL-LAD are similar to those of LSD, albeit with some subtle differences. It is believed to be either equally or moderately less potent than LSD, with an active dose typically ranging from 75 to 150 micrograms. Users often describe AL-LAD as being more visually oriented, while offering a less introspective headspace. Additionally, it has a moderately shorter duration and is generally considered to be a less anxiety-provoking and challenging alternative to LSD.

Chemical Structure

AL-LAD, or 6-allyl-6-nor-lysergic acid diethylamide, is a semisynthetic alkaloid from the lysergamide family. It is a structural analog of lysergic acid, featuring an N,N-diethylamide functional group. The chemical structure of AL-LAD includes a bicyclic hexahydroindole fused to a bicyclic quinoline group (nor-lysergic acid). Unlike LSD, AL-LAD does not have a methyl group at R6 of its nor-lysergic acid skeleton, as indicated by the "nor-" prefix. Instead, it is substituted at R6 with an allyl group, which consists of a methylene bridge linked to a vinyl substituent. A N,N-diethyl carboxamide is attached at carbon 8 of the quinoline.

Chirality

AL-LAD is a chiral compound with two stereocenters located at R5 and R8. The compound, also referred to as (+)-D-AL-LAD, has an absolute configuration of (5R, 8R). The other three stereoisomers of AL-LAD are not known to possess psychoactive properties. Notably, AL-LAD does not cause a color change with the Marquis, Mecke, or Mandelin reagents, but it does turn purple with Ehrlich's reagent due to the presence of the indole moiety in its structure.

Pharmacological Profile

AL-LAD is thought to act as a 5-HT2A partial agonist, with its psychedelic effects likely arising from its efficacy at the 5-HT2A receptors. However, the specific role of these interactions and how they contribute to the psychedelic experience remains an area of scientific inquiry.

Comparative Potency

AL-LAD shares many characteristics with its parent compound, LSD. In human studies, it appears to be roughly equal in potency, if not slightly less so, while exhibiting a similar mechanism of action. However, the onset and duration of effects are generally shorter, remaining qualitatively less intense and more manageable, possibly due to more rapid catabolism. Interestingly, in rat studies, AL-LAD was found to be approximately twice as potent as LSD, although anecdotal reports from human users suggest it may be equipotent or slightly less psychoactive than LSD.

Subjective Effects

While the subjective effects of AL-LAD largely overlap with those of LSD, users frequently report a significantly shorter duration and reduced discomfort in terms of negative physical side effects and anxiety. Some individuals have suggested that AL-LAD could serve as an effective introductory psychedelic, alongside other shorter-lasting and more manageable psychedelics like 2C-B or 4-HO-MET.

AL-LAD 150mcg Blotters is for research use only and not intended for human consumption!

---

AL-LAD 150mcg Blotters stock last updated at: April 2025